Clene Inc. is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases. Based in Utah, the company develops novel clean-surfaced nanotechnology (CSN) therapeutics targeting cellular energy impairments common to many neurological conditions. Their lead drug candidate, CNM-Au8, is being studied in various clinical trials for conditions such as amyotrophic lateral sclerosis (ALS).
The company's innovative approach aims to restore and protect neuronal health and function through its nanotherapeutic platform. Clene's pipeline includes catalytic nanocrystals designed to address energy impairments at the cellular level, potentially offering new treatment options for patients with neurodegenerative diseases. The company's commitment to advancing these therapies positions it at the forefront of neurological research and development.